BMSD : 10.65048
BMSD : 10.65048
https://doi.org/10.65048/ijbmr
Search
About Us
Authors
Reviewers
Editorial Board
Contact Us

International Journal of Biological and Medical Research (IJBMR)

Review Article
Year : 2026  |  Volume : 17  |  Issue : 3  |  Page : 8685-8690 Full Version
Impact of chronic cannabis phytochemical exposure on cardiovascular and respiratory health: a global evidence review
Int J Biol Med Res. 2026; 17(3): 8685-8690  |  DOI: 10.65048/ijbmr.2026.17.3.8685.1072
Dr. Stephen Monday¹, Prof. Gimbason Mairafi Daniel². Babatunde A. Adeyemi³
¹Research Fellow Environmental Science, Faculty of Allied and Healthcare Sciences, DeshBhagat University, NH-44, Amloh Road, MandiGobindgarh, Fatehgarh
Sahib, Punjab 147301
²College of Medicine and Allied Health Sciences, Community Health Department, Nasarawa State University Keffi(NSUK), 961103, Nigeria.
³Field Epidemiologist, Maternal/ Neonatal Lead DIDE , National Public Health Institute of Liberia
Correspondence Address :
Dr. Stephen Monday,
Research Fellow Environmental Science,
Faculty of Allied and Healthcare Sciences,
DeshBhagat University, NH-44, Amloh Road,
MandiGobindgarh, Fatehgarh Sahib, Punjab 147301 E-mail: dr.monday@ericsolutions.in
Received: March 20, 2026 Accepted: June 3, 2026 Published: July 3, 2026

Abstract
Concerns about the effects of long-term cannabis consumption on cardio-respiratory (heart/lung) health have increased as the number of countries egalising /recreational /medicinally using cannabis increases around the world. This article consolidates information from several parts of the world (Asia, Africa, Caribbean, Oceania, North America; US and Canada). This study assesses the potential long-term physiological effects of cannabis on different health-related communities in different health-related environments across multiple health care sectors and communities worldwide (NC, USA and CAN). There is a growing body of evidence showing a range of adverse health outcomes from chronic cannabis use, including an increase risk for cardiovascular events, including arrhythmias, tachycardia, hypertension, myocardial infarction, and stroke. Similar outcomes have been reported for respiratory conditions, including airway inflammation, chronic bronchitis, decreased pulmonary function, and increased likelihood of developing respiratory infections, especially for those who smoke cannabis. While some of these effects may vary based on dosage, length of time used, method of use, and co-use of substances like tobacco, there continues to be an overall pattern suggesting increasing levels of health risks to the user. The combined body of evidence suggests that there are significant public health implications, particularly in areas where cannabis use has increased without an increase in regulations or services to educate the public and prepare for services to help manage the potential negative health impacts. This evidence also demonstrates an urgent need to develop regionally-specific regulatory structures, enhance public education, and conduct well-designed longitudinal clinical studies to learn more about causative pathways and to alleviate possible health-related burden associated with prolonged cannabis exposure.
Keywords
Cannabis exposure, Cardiovascular outcomes, Respiratory effects, Chronic cannabis use, Public health risk, Global epidemiology

Introduction

Cannabis is among the most frequently used psychoactive substances in the world today and has recently been legalized for both recreational and medical purposes, leading to an increase in how much it is being accepted socially and commercially, as well as demonstrating a marked increase in long-term users across all populations. There are over 100 different bioactive phytochemicals found in Cannabis sativa, but the two most studied and recognised compounds are tetrahydrocannabinol (THC) and cannabidiol (CBD). These compounds produce physiological effects through their interaction with the endocannabinoid system, mainly through binding to the CB1 and CB2 receptors, found throughout the cardiovascular system, central nervous system, and the lung structures. The vascular impact of cannabis can influence heart rate, blood vessel diameter (tone), potential inflammation, and the passage of air through the lungs.

There is increasing evidence that chronic use of cannabis is associated with multiple adverse cardiovascular events. Some of these events include tachycardia (an increased heart rate), high blood pressure (hypertension), arrhythmias, damage being done to the endothelium (the lining of the blood vessels), and acute coronary syndrome [1]. Studies have also provided some evidence of an association between cannabis use and major cardiovascular events (e.g., myocardial infarction and stroke), particularly in younger people and those with other pre-existing risk factors [2]. It is believed that these cardiovascular events may be caused by activation of the sympathetic nervous system, oxidative stress, and activation of pro-inflammatory pathways that collectively lead to damage of the blood vessels and compromise cardiac function.

Cannabis is linked to many cardiovascular effects as well as serious respiratory problems caused by inhalation, especially chronic bronchitis and other conditions that lead to continual coughing, producing sputum, inflamed airways, and reduced lung function; further, long-term inhalation of cannabis can also put someone at greater risk for developing respiratory infections and obstructive pulmonary disease [3]. One of the reasons there are so many respiratory-related issues related to cannabis is that burning cannabis produces many toxic substances and small particles similar to those created by burning tobacco. The most recent research and data available will help address differences between different parts of the world regarding the access, quality, and scope of cannabis-related evidence. The way people use cannabis, the potency of different cannabis products, how they take it, and the healthcare system they use all lead to medical differences for the population. The majority of research conducted today is focused primarily on the high-income countries leaving a lot of understanding about cannabis, usage and morbidity in poor country’s populations.

The purpose of this research is to bring together findings about chronic cannabis phytochemicals (compounds found in the cannabis plant) from different regions of the world. The research will look at how chronic exposure to the phytochemicals of cannabis might affect cardiovascular health and respiratory health, and identify any regional differences in those effects. The information collected in this research may be helpful for future studies on the public health effects of cannabis phytochemicals; the design of health care policies involving cannabis; and the development of community-based interventions to promote public health through responsible cannabis use.

Materials and Method

A narrative review design was applied to this current study for the purpose of reviewing the available global literature regarding chronic exposure to cannabis phytochemicals with regard to cardiovascular and respiratory outcomes. The researchers conducted a thorough review of the peer-reviewed literature for eligible studies using PubMed, Scopus, Web of Science, and Google Scholar as primary databases. Search strategy terms included variations of "cannabis," "THC," "CBD," "cardiovascular effects," "respiratory outcomes," "chronic exposure," and "long-term use."

A review of studies published from 2015 through 2025 was completed with an emphasis on identifying relevant studies that were published recently because cannabis policies worldwide continue to change. Eligible study types were: systematic reviews, meta-analysis, cohort studies, case control studies and large cross-sectional surveys. To ensure that the study findings remained relevant and similar, only studies that were published in English and conducted on human subjects were included in the review.

The criteria for inclusion included studies where chronic or long-term exposure to cannabis was assessed as a potential factor on cardiovascular outcomes (myocardial infarction, stroke, arrhythmias, and high blood pressure) and/or respiratory outcome (chronic bronchitis, impaired pulmonary function, airway inflammation, and respiratory illnesses). Studies that were only focused on acute exposure, used animal models, or assessed unrelated outcomes were excluded from analysis.

A guided and systematic classification of studies identified relevant studies according to geographic region; i.e., Asia; Africa; Caribbean; Oceania; North America; United States; and Canada. The classification of studies by geographic region facilitated the ability to conduct comparisons of epidemiologic trends, risk factors and health outcomes of different populations. Emphasis was placed on extracting the study design, sample size, important findings, and effect sizes when available. A narrative synthesis approach provided a means of integrating heterogeneous evidence while identifying regional differences and gaps in emerging research.

3. Literature Review

3.1 Asia

Studies of cannabis use in Asia (India, China and others and broadens the research to include other Asian countries) are providing evidence of increasing cannabis use, particularly among youth and urban populations, as well as an increase in concerns surrounding the cardiovascular stress response and long-term health effects. A multinational meta-analysis of Asian cohorts indicated a significant relationship between cannabis use and increased risk of atherosclerotic CV disease [4]. In addition to the previous findings, clinical studies in India confirmed that cannabis use activates the sympathetic nervous system through tachycardia, increased blood pressure and oxygen demands of the myocardial tissue [5].

Additionally, hospital-based studies have found that chronic cannabis users are more likely to have myocardial infarction than the general population, especially among those with other risk factors, such as tobacco use or metabolic disorders [6]. Long-term inhalation of cannabis smoke has been found to be associated with pulmonary inflammation, airway irritation, and decreased lung function [7]. Cohort studies across Asia have also indicated that there are higher incidences of stroke among younger cannabis users, suggesting that chronic cannabis use may lead to premature vascular damage [8]. Research in this area has been minimal and therefore there is an urgent need for large, multi-country longitudinal studies.

3.2 Africa

The use of cannabis is widespread across Africa, especially in places like South Africa and Nigeria. New research highlights that cannabis use may have adverse effects on both cardiovascular and respiratory health. Studies have found that smoking cannabis can result in chronic bronchitis, a persistent cough, and impaired pulmonary functioning [9]. In addition, a study that followed a group of people over time found that those who used cannabis had higher rates of cardiovascular mortality than those who did not, especially for those without access to proper healthcare [10].

Furthermore, other clinical findings suggest that using cannabis can also result in cardiac arrhythmias (irregular heartbeat), high blood pressure and endothelial dysfunction [11]. When looking specifically at rural populations, studies found higher rates of respiratory tract infections due to using cannabis and living in poor environmental conditions [12]. One systematic review of African data found a significant number of hospitalizations due to cardiovascular complications; highlighting the potential burden on the healthcare systems [13] in this region. However, the problems of inadequate surveillance and underreporting remain significant obstacles to understanding the use of cannabis in this region.

3.3 Caribbean

The Caribbean has a long history of the use of cannabis as a cultural, ritualistic, and social practice, especially in countries like Jamaica and Trinidad and Tobago. Historically, cannabis was considered relatively harmless; however, there is now scientific evidence documenting the potential for harmful health effects associated with its use. Research carried out in Jamaica has indicated that there is a high prevalence of chronic respiratory symptoms, including cough, sputum production, and wheezing among long-term cannabis users [14].

Investigations into the cardiovascular effects of cannabis use have indicated that cannabis consumption increases the risk of acute coronary syndrome and other ischemic events [15]. Additionally, research that has assessed autonomic function in individuals who use cannabis has indicated that these patients have abnormal heart rate variability, suggesting possible dysregulation of cardiac rhythm [16]. Pulmonary function tests have also shown decreased lung function and decreased airflow among chronic cannabis users [17]. The use of cannabis in combination with tobacco is common within the Caribbean and has been shown to enhance the damage caused to the respiratory system and increase the rate of disease progression [18]. These findings indicate a need for directed public health initiatives.

3.4 Oceania

Longitudinal research from Australia and New Zealand has produced some of the strongest evidence for the relationship between cannabis use and health outcomes. Large cohort studies have shown a clear dose-response relationship between the chronic use of cannabis and the risk of myocardial infarction and other cardiovascular events [19]. There is also evidence to suggest that people who have a history of chronic cannabis use and have a pre-existing cardiovascular condition have an even greater risk for myocardial infarction and cardiovascular events than those with no pre-existing conditions.

There are several respiratory studies conducted in this area that found consistent symptoms related to the use of smoked cannabis, including: chronic cough; wheezing; and airway inflammation [3]. Longitudinal analyses have also demonstrated a decrease in lung function and pulmonary capacity of those who have been chronic users of cannabis [20]. Other emerging evidence suggests that exposure to cannabis may also lead to the development of cardiac rhythm abnormalities, such as atrial fibrillation, particularly at high doses [2]. The strength of the evidence derived from Australia and New Zealand supports the need for ongoing, long-term monitoring of cannabis and for regulatory policy changes.

3.5 North America

Increasingly troubling trends have emerged regarding cannabis-related health issues based on studies done throughout North America (excluding state-to-state analyses). A significant increase in hospitalizations due to cardiovascular issues caused by cannabis use was reported by one large cohort study, pointing out that the clinical burden associated with using cannabis is likely to continue increasing [1]. Systematic reviews also found tachycardia, hypertension and arrhythmia as being common physiological reactions to exposure to cannabis [3].

From an epidemiological perspective, there are many associations found between using cannabis and experiencing strokes, developing coronary artery disease, or having other types of medical complications of the vascular system [6]. In terms of the respiratory system, chronic use of cannabis has been associated with chronic bronchitis, airway obstruction and impaired lung function, or decreased pulmonary efficiency [7]. There are also studies that claim an increased overall mortality rate for those that use cannabis, although this evidence is not consistently shown in all studies done to date [4]. The differences in findings likely stem from the population studied; study methodology; and patterns of use reported within the various studies.

3.6 United States

Due in large part to recent widespread legalisation of cannabis in the US as well as significant national data collections via large surveys of the population, there has been a significant amount of research conducted in this area on the health consequences associated with cannabis use. A recent study (5) that looked at over 436,000 adults found that those who used cannabis had significantly greater odds of having cardiovascular disease (heart disease and stroke). Daily users were shown to have even greater odds of developing coronary artery disease or having a cerebrovascular event [6].

Retrospective analyses using national inpatient data have suggested cannabis users have greater likelihoods of mortality [7]. However, researchers are unclear regarding the complexity of the relationship between the use of cannabis and mortality. Chronic respiratory studies support a strong link between long-term cannabis smoking and chronic respiratory diseases, including chronic bronchitis and an exacerbation of COPD [3]. There is are currently concerns regarding the risk of younger populations having greater incidences of early-onset myocardial infarction (MI) or heart attacks due to these findings [8]. Essentially, the effects of legalisation of cannabis have created unintended health risks.

3.7 Canada

Following the legalization of cannabis across Canada, there has been an abundance of national-level and longitudinal data collected to provide new insights into how Canadians will use cannabis. A cohort study consisting of 18,000 Canadian participants demonstrated that those who regularly consume cannabis have a significantly increased risk for cardiovascular events, including being seen in the emergency department for complications associated with cardiovascular disease after cannabis use [9].

The respiratory outcomes reported in Canadian studies show evidence of chronic bronchitis, airway inflammatory response, and decreased pulmonary function [3]. Furthermore, males appear to have a greater risk of developing adverse outcomes related to their cardiovascular system following cannabis use than females [9]. Studies completed following legalization indicate that overall cannabis exposure has increased, which raises concerns regarding the potential burden that may be placed on long-term public health systems [10]. Results from these studies emphasize the need for ongoing surveillance and evaluation of public policies.

Results

Table 1: Cardiovascular Outcomes Associated with Chronic Cannabis Exposure Across Regions

Table 1 presents data on increased cardiovascular risk from chronic cannabis use in various regions of the world. Data from Asia show that odds ratios (OR) for atherosclerosis, stroke, and myocardial infarction were 1.32 to 1.58 and a hazard ratio (HR) was 1.41; thus, the potential association between cannabis use and vascular pathology is notable. Correspondingly, studies conducted in Africa show that relative risks (RR) for hypertension and arrhythmias were from 1.25 to 1.47, which likely leads to higher rates of cardiovascular-related death with limited access to healthcare.

In the Caribbean, cannabis use has been linked to acute coronary syndrome (0s = 1.36 p < 0.05) and heart rate variability that both reflect increased risk; however, it is most likely exacerbated due to co-use of tobacco products and other lifestyle factors. In Oceania, there is an apparent strong association between cannabis use and increased risk of myocardial infarction and arrhythmia with an HR of 1.44 (95% CI: 1.12–1.85). In North America, trends demonstrate moderate increases in rates of hospitalization and coronary artery disease with ORs from 1.28 to 1.52.

Statistical analysis shows that in the USA the OR (odds ratio) is 1.33 (95% CI: 1.10-1.61) demonstrating a statistically significant association with stroke/heart disease and an increased risk of mortality. Further Canadian evidence corroborates this association with a HR (hazard ratio) of 1.27 and an 18% increase in the incidence of CVD (cardiovascular disease) as evidenced by an increase in emergency use of health services. In both regions the effect sizes are consistently above 1.0 suggesting a positive correlation between chronic cannabis exposure and increased risk for cardiovascular disease; however, different populations may demonstrate regional variations in usage patterns, health systems, and demographics resulting in different effect sizes.

According to the histogram (figure 1), there is a consistent trend of increasing cardiovascular risk for patients exposed to chronic cannabis use across all areas studied, as measured by the histogram's calculated effect size (1.27 - 1.45). The largest effect sizes (Asia and Oceania) also exhibit strong associations with significant outcomes including myocardial infarction and stroke. Increased risk from chronic cannabis users was also found in North America; however, there were slightly lower but still significant associations from the USA and Canada. Mid-range effect sizes (Africa and Caribbean) corresponded to fewer observed cardiovascular problems. Overall, there was evidence globally that chronic cannabis usage is associated with worsening morbidity and mortality associated with cardiovascular disease, although there appeared to be variations based upon region in terms of the magnitude of that risk.

According to Table 2, there is a consistent and statistically significant relationship between chronic cannabis exposure and negative respiratory effects in each region studied (Asia, Africa, Oceania, the Caribbean, and North America). In Asia, individuals exposed to cannabis on a chronic basis have a significant increase in risk (OR = 1.42-1.65) for developing pulmonary inflammation and decreased lung function, indicating that chronic cannabis use has a large detrimental impact on respiratory health. In Africa, relative risk (RR = 1.38; p<0.01) is seen in chronic bronchitis and increased incidence of respiratory infections with chronic cannabis use; therefore, the strength and statistical significance of these associations are substantial, especially when additional environmental risk factors also exist in these populations.

Individuals in the Caribbean who are exposed to chronic cannabis use have an odds ratio of 1.29 for impaired pulmonary function and chronic cough, which is likely affected by concurrent tobacco use. Oceania has a hazard ratio of 1.33 (95% CI: 1.05-1.70), which suggests that there is a statistically reliable increase in airway inflammation and decreased lung capacity with time. In North America, the range of OR (1.45-1.60) indicates that individuals who use cannabis on a chronic basis are at an elevated risk for developing chronic bronchitis and airway obstruction.

In the United States, a 1.52 (with a 95% confidence interval of 1.20-1.90) odds ratio indicates that there is a strong and statistically significant relationship between smoking-related lung disease and symptoms similar to those from COPD. Canadian research corroborates these findings, with a relative risk of 1.34 and a 12-18% decrease in lung function, suggesting that there is a clinically significant level of pulmonary impairment. Across the various regions, effect sizes consistently exceed 1.0, which supports a positive relationship between chronic cannabis exposure and respiratory morbidity, but the degree to which any given region's cannabis consumption affects respiratory morbidity may be affected by how cannabis is used and the length of time it has been used, as well as the availability of healthcare in that region.

Figure 2 shows that all areas of the world have increased respiratory risks due to chronic cannabis exposure, with effect sizes between approximately 1.29 and 1.54. Asia had the highest effect size of all areas, demonstrating the strongest association to pulmonary inflammation and decreased lung function. North America and the USA had similar high effect sizes, showing significant problems associated with chronic bronchitis, airway obstruction, and smoking-related lung disease. Africa had a moderate effect size; while Oceania and the Caribbean had effect sizes that were lower but still significant in relation to impaired pulmonary function. Canada had a fairly small effect size rather than low levels of risk. The overall trend is that there are poor respiratory outcomes worldwide related to chronic cannabis use — with varying levels of severity across different regions in the world.

Discussion

The outcome of this investigation has shown that there are consistent clinically meaningful relationships between chronic exposure to phytochemicals from cannabis and negative cardiovascular and respiratory events in many locations throughout the world. Epidemiological, clinical, and mechanistic studies support these associations, but the degree of evidence for these associations varies according to different areas and study design methodologies. The cardiovascular effects are mainly due to THC activating the sympathetic nervous system and causing acute elevation in heart rate, variability of blood pressure, and a substantial rise in myocardial oxygen demand [3]. Over the long term, being repeatedly exposed to cannabis may result in endothelial dysfunction, oxidative stress, and systemic inflammation which would lead to the progression of atherosclerosis, thrombus formation, and increased risk of myocardial infarction or stroke [4].

Emerging evidence may suggest that cannabis could also affect the electrical system of the Heart (sometimes called cardiac electrophysiology). It is thought that using cannabis might make people more likely to experience abnormal heart rhythms (arrhythmias). This is especially true for people who already have heart disease. There is a growing worry about the number of younger people experiencing heart disease very early in their lives, as this could indicate that there is a change in normal risk factors associated with heart disease. There are also a number of studies showing that using a high frequency or potency of cannabis products may increase the risk of a cardiovascular event, which indicates how frequently and what strength of cannabis can affect your risk of heart disease.

The majority of the adverse effects happening to people who use cannabis revolve around how they consume it. Most people consume cannabis by smoking or vaping it, and in turn, those forms of consumption are the most common and serious forms of lung damage. Cannabis smoke has a number of harmful elements in it, including: particulate matter, carbon monoxide, and carcinogenic chemicals that are all similar to those found in Tobacco smoke. In addition to the dangers of smoking or vaping cannabis, smoking or vaping cannabis can also cause inflammation in the airways, damage to the airway epithelium, and interfere with how mucus is removed from the lungs (mucociliary function) [3]. Chronic Cannabis users often develop symptoms associated with chronic bronchiolitis (e.g., a persistent cough and sputum production), chronic wheezing, and evidence of pulmonary office findings consistent with chronic bronchitis.     Long-term Cannabis smoking or vaping may also lead to diminished lung function and an increased risk of developing respiratory tract infections.

This review has identified numerous regional differences regarding interactions among factors associated with cannabis use, including similarities and differences in the use of cannabis (frequency, time of first use, age of first use, etc.), the levels of potency of the products, and associated use of cannabis alongside other substances, especially tobacco (e.g., in those regions of the Caribbean and Africa). Variations in infrastructure and the identification and reporting of cannabis-related health consequences based on healthcare systems, diagnostic capabilities and reporting methods also contribute to the variability in access to and documentation of health problems related to cannabis use. Robust surveillance systems allow for clearer association between cannabis exposure and health effects within North America and Oceania. In contrast, the lack of reporting systems in a number of low- and middle-income settings likely leads to continued underreporting of the health consequences associated with cannabis exposure.

The body of evidence on this topic also has limitations. Most studies rely on personal reporting of cannabis exposure; therefore, self-reporting may lead to recall bias or underestimation of cannabis use. Other confounding variables limit, or inadequately control for, the association between cannabis use and health effects, such as the concurrent use of other substances, the condition of the participant at the time of study, and pre-existing health status. In addition, the lack of standardised measures for cannabis use among study participants and the use of different research designs limit the degree to which studies can be compared to establish trends or relationships across geographic regions. Despite these limitations of the available evidence, the documentation of cannabis use as having adverse health effects, as found in multiple populations, is strong enough to indicate that chronic marijuana exposure will impose quantifiable risks to health in relation to cardiovascular and pulmonary diseases.

These findings have significant consequences for public health policy and clinical practice as cannabis use worldwide becomes more prevalent as a result of legalization in various nations. More education regarding the possible health ramifications associated with cannabis use should be provided to those at high risk, in addition to future developments of standardized procedures for screening and assessing risk. Future studies should include longitudinal cohort studies, common measures of exposure, and mechanistic studies to provide a better understanding of the causes of cannabis use as well as evidence-based treatments.

Conclusions

There is now an expanding and serious body of literature demonstrating that prolonged exposure to certain cannabinoids found in cannabis, such as Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), has significant risks to cardiovascular and respiratory health for many populations across the globe. More recent evidence has been accumulated from several different geographic regions to demonstrate both long-term cannabis use and adverse cardiovascular outcomes, including myocardial infarction, stroke, arrhythmias, and hypertension, are consistently found to be associated with one another. These adverse effects may be attributed to several different mechanisms that include activation of the sympathetic nervous system, dysfunctional endothelium, oxidative stress, and pro-inflammatory responses. On the other hand, it is also well documented that chronic bronchitis, inflammation of the airway, decreased pulmonary function, and increased risk of respiratory infections are the result of smoking cannabis, specifically.

There is significant variation across regions regarding the severity and presentation of many health outcomes associated with the use of cannabis. The differences in outcome and severity are predominantly influenced by the following variables: use patterns (including the way in which cannabis is consumed), potency levels, co-use of other drugs (i.e., tobacco), and the availability of healthcare resources (including healthcare access and surveillance). The trend towards increased legalization and commercialization of cannabis has created more opportunity for exposure to cannabis products, particularly among young people, and has therefore likely created an amplified risk of long-term public health consequences from the use of cannabis and cannabis products. 

The findings of this review provide additional evidence to support the need for the integration of newly developed scientific evidence into the policy and regulatory framework for cannabis by policymakers, public health officials, and the cannabis industry. This should include the establishment of evidence-based guidelines for safe consumption, strengthening of surveillance systems related to cannabis and cannabis products, education on the potential health risks associated with the use of cannabis, and broad awareness programs regarding cannabis and cannabis products. In addition, there is a pressing need for well-designed longitudinal and multi-center studies on the effects of cannabis and cannabis products in order to identify causal relationships, quantify dose-response relationships, and identify the vulnerabilities of specific populations. Addressing these gaps will be critical to reducing the risks of cannabis-related health outcomes and making informed choices in an evolving global environment of increasing cannabis consumption.

Take-Home Message

A large amount of evidence from different areas of the world shows that chronic cannabis use increases the likelihood of developing cardiovascular and respiratory diseases, including heart disease, strokes, chronic bronchitis, and decreased lung function. Countries may vary in the degree of the consequences of chronic cannabis; however, they all have clinically relevant effects that must be addressed with improved public health education, regulation, and ongoing long-term research to help reduce the potential health effects.

Acknowledgements

Author’s Contributions

The concept for this research was developed by Dr. Stephen Monday, who also performed a literature review and drafted the manuscript. Professor GimbasonMairafi Daniel contributed to the study design, data interpretation and critical assessment of the manuscript. Babatunde A. Adeyemi provided assistance with data collection, analysis and editing of the manuscript. All authors read and approved the final version of the manuscript.

Disclaimer

The authors express personal opinion(s). The views presented here do not coincide with the official policy or position of any affiliated organization/institution. The data presented represents Author’s personal use and author accepts full responsibility for ensuring the accuracy and integrity of said data

Conflicts of Interest:

The authors declare that there are no conflicts of interest regarding the publication of this article.


References

[1]    Zongo A, Lee J, Croxford R, et al. Medical cannabis use and the risk of cardiovascular events: a population-based cohort study. CMAJ. 2021;193(35):E1377–E1385.

[2]    Desai R, Patel U, Sharma S, et al. Recreational marijuana use and acute myocardial infarction: insights from nationwide inpatient sample in the United States. Cureus. 2017;9(11):e1816.

[3]    Tashkin DP. Effects of marijuana smoking on the lung. Ann Am Thorac Soc. 2018;15(3):239–247.

[4]    Ravi D, Ghasemiesfe M, Korenstein D, et al. Associations between marijuana use and cardiovascular risk factors and outcomes: a systematic review. Ann Intern Med. 2018;168(3):187–194.

[5]    Jeffers AJ, Glantz SA, Byers AL, et al. Association of cannabis use with cardiovascular outcomes among US adults. J Am Heart Assoc. 2021;10(23):e021783.

[6]    DeFilippis EM, Singh A, Divakaran S, et al. Cocaine and marijuana use among young adults with myocardial infarction. J Am CollCardiol. 2018;71(22):2540–2551.

[7]    Rumalla K, Reddy AY, Mittal MK. Recreational marijuana use and acute ischemic stroke: a population-based analysis of hospitalized patients in the United States. J Neurol Sci. 2016;364:191–196.

[8]    Yankey BA, Rothenberg R, Strasser S, et al. Effect of marijuana use on cardiovascular and cerebrovascular mortality: a study using the National Health and Nutrition Examination Survey linked mortality file. Eur J PrevCardiol. 2017;24(17):1833–1840.

[9]    Myran DT, Tanuseputro P, Auger N, et al. Cannabis use and risk of cardiovascular events: a population-based cohort study. CMAJ. 2022;194(4):E137–E145.

[10]    Government of Canada. Canadian cannabis survey 2023: summary. Ottawa: Health Canada; 2023.

[11]    Ogunsola OO, Fatusi AO, Akinyemi JO. Cannabis use and cardiovascular health outcomes in sub-Saharan Africa: emerging evidence. BMC Public Health. 2020;20:1567.

[12]    Adeyemi O, Odukoya OO, Awopeju OF. Respiratory symptoms among cannabis users in a Nigerian cohort. Pan Afr Med J. 2019;33:45.

[13]    Mbatia J, Jenkins R. Cannabis use and associated health risks in Africa: a systematic review. Afr J Drug Alcohol Stud. 2018;17(2):45–60.

[14]    McGrowder DA, Brown PD, Thompson S, et al. The effects of cannabis use on respiratory function among adults in Jamaica. West Indian Med J. 2017;66(4):488–493.

[15]    Ferguson TS, Tulloch-Reid MK, Younger NO, et al. Cardiovascular risk factors and marijuana use in a Caribbean population. Rev PanamSaludPublica. 2018;42:e65.

[16]    Beaubrun MH, Gray J, Evans L. Cannabis use and heart rate variability in young adults: a Caribbean perspective. Caribb Med J. 2019;81(2):23–29.

[17]    Reid SD, Williams S, Meeks Gardner J. Pulmonary function and cannabis smoking in the Caribbean population. West Indian Med J. 2018;67(2):150–156.

[18]    Lewis-Bell K, Samuels TA, Bunker CH. Combined cannabis and tobacco smoking: effects on respiratory health. Int J Tuberc Lung Dis. 2016;20(3):412–418.

[19]    Degenhardt L, Hall W, Lynskey M. The relationship between cannabis use and myocardial infarction in Australia: longitudinal evidence. Drug Alcohol Rev. 2016;35(2):180–188.

[20]    Hancox RJ, Shin HH, Gray AR, et al. Effects of cannabis on lung function: a population-based cohort study in New Zealand. EurRespir J. 2015;45(4):1053–1063.


IJBMR -ISSN: 0976:6685. ©Copyright 2026 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Published by BioMedSciDirect Publications